Supernus Pharmaceuticals, Inc. (SUPN): CEO sold ~$1.55M

~$1.55M

Approx. value · 39K sh @ $40.24

1.03M

Holds after · shares reported

Traded

Aug 6, 2025

Filed

Aug 8, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 6, 2025 · this disclosureInsiderCEO sold ~$1.55M of SUPN shares in the open market

What came next

1. Aug 6, 2025Insider · 1 personInsiders: 2 sales (~$4.3M)
2. Aug 14, 2025Insider · 2 peopleInsiders: 2 sales (~$542K)
3. Aug 22, 2025Insider · 3 peopleInsiders: 3 sales (~$655K)
4. Aug 25, 2025Insider · 3 peopleInsiders: 3 sales (~$713K)
5. Aug 27, 2025Insider · 2 peopleInsiders: 2 sales (~$641K)
6. Aug 28, 2025InsiderCEO sold ~$1.09M of SUPN shares in the open market
7. Sep 5, 2025InsiderCEO sold ~$2.56M of SUPN shares in the open market
8. Sep 8, 2025InsiderCEO sold ~$293K of SUPN shares in the open market
9. Sep 12, 2025InsiderOfficer sold ~$229K of SUPN shares in the open market
10. Sep 22, 2025InsiderCEO sold ~$780K of SUPN shares in the open market
11. Sep 23, 2025InsiderCEO sold ~$1.39M of SUPN shares in the open market
12. Sep 29, 2025InsiderCEO sold ~$491K of SUPN shares in the open market
13. Oct 9, 2025CongressDisclosed partial sale of SUPN — reported range $1,001 - $15,000
14. Oct 21, 2025Company filing · Form 8-K · ResultsReported its results
15. Nov 4, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Supernus Pharmaceuticals, Inc.

OQRO holds no insider, Congress, fund or contract record for Supernus Pharmaceuticals, Inc. dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its SUPN page.

Other recent filings by Jack A. Khattar, President, CEO

• SEC Form 4 at Supernus Pharmaceuticals, Inc. (SUPN)Sep 30, 2025
• SEC Form 4 at Supernus Pharmaceuticals, Inc. (SUPN)Sep 24, 2025
• SEC Form 4 at Supernus Pharmaceuticals, Inc. (SUPN)Sep 23, 2025
• SEC Form 4 at Supernus Pharmaceuticals, Inc. (SUPN)Sep 9, 2025
• SEC Form 4 at Supernus Pharmaceuticals, Inc. (SUPN)Sep 8, 2025

The full history of Jack A. Khattar, President, CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Supernus Pharmaceuticals, Inc.

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRJul 29, 2026
• SEC Form 13F-HRMay 13, 2026
• SEC Form 13F-HRApr 28, 2026
• House Clerk periodic transaction reportApr 7, 2026

Everything OQRO holds on this company is on its SUPN page.